[go: up one dir, main page]

MX2015014662A - Polipeptidos diseñados de fenilalanina amonio liasa. - Google Patents

Polipeptidos diseñados de fenilalanina amonio liasa.

Info

Publication number
MX2015014662A
MX2015014662A MX2015014662A MX2015014662A MX2015014662A MX 2015014662 A MX2015014662 A MX 2015014662A MX 2015014662 A MX2015014662 A MX 2015014662A MX 2015014662 A MX2015014662 A MX 2015014662A MX 2015014662 A MX2015014662 A MX 2015014662A
Authority
MX
Mexico
Prior art keywords
polypeptides
engineered
phenylalanine ammonia
pal
ammonia lyase
Prior art date
Application number
MX2015014662A
Other languages
English (en)
Other versions
MX366196B (es
Inventor
Benjamin Mijts
Xiyun Zhang
Gjaly W Huisman
Nicholas J Agard
Jonathan Vroom
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Publication of MX2015014662A publication Critical patent/MX2015014662A/es
Publication of MX366196B publication Critical patent/MX366196B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01005—Phenylalanine ammonia-lyase (4.3.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)

Abstract

La presente invención proporciona polipéptidos diseñados de fenilalanina amonio liasa (PAL) y composiciones de los mismos, así como polinucleótidos que codifican a los polipéptidos de fenilalanina amonio-liasa (PAL); en algunas modalidades, los polipéptidos PAL diseñados son optimizados para proporcionar una mejor actividad catalítica, así como una reducción de la sensibilidad a la proteólisis y con mayor tolerancia a los niveles de pH ácido; en algunas modalidades los polipéptidos PAL diseñados están desinmunizados; la invención también se refiere al uso de las composiciones que comprenden los polipéptidos PAL diseñados con fines terapéuticos e industriales.
MX2015014662A 2013-04-18 2014-04-17 Polipeptidos diseñados de fenilalanina amonio liasa. MX366196B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361813586P 2013-04-18 2013-04-18
US201361897932P 2013-10-31 2013-10-31
PCT/US2014/034500 WO2014172541A2 (en) 2013-04-18 2014-04-17 Engineered phenylalanine ammonia lyase polypeptides

Publications (2)

Publication Number Publication Date
MX2015014662A true MX2015014662A (es) 2016-03-03
MX366196B MX366196B (es) 2019-07-01

Family

ID=51729192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014662A MX366196B (es) 2013-04-18 2014-04-17 Polipeptidos diseñados de fenilalanina amonio liasa.

Country Status (27)

Country Link
US (17) US9611468B2 (es)
EP (3) EP2986722B1 (es)
JP (5) JP6637410B2 (es)
KR (1) KR102218930B1 (es)
CN (2) CN105324483B (es)
AU (2) AU2014253900C1 (es)
CA (1) CA2909719C (es)
CY (1) CY1121891T1 (es)
DK (2) DK2986722T3 (es)
EA (1) EA034034B1 (es)
ES (2) ES2890955T3 (es)
HR (1) HRP20190928T1 (es)
HU (2) HUE043549T2 (es)
IL (1) IL242067B (es)
LT (1) LT2986722T (es)
MX (1) MX366196B (es)
MY (1) MY193198A (es)
NZ (1) NZ713396A (es)
PE (1) PE20151775A1 (es)
PH (1) PH12015502412B1 (es)
PL (1) PL2986722T3 (es)
PT (1) PT2986722T (es)
RS (1) RS58802B1 (es)
SG (1) SG11201508598YA (es)
SI (1) SI2986722T1 (es)
SM (1) SMT201900315T1 (es)
WO (1) WO2014172541A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102218930B1 (ko) 2013-04-18 2021-02-23 코덱시스, 인코포레이티드 조작된 페닐알라닌 암모니아 리아제 폴리펩티드
HUE056444T2 (hu) * 2014-04-16 2022-02-28 Codexis Inc Génmódosított tirozin-ammónia-liáz
WO2016183531A1 (en) 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia
CN106636048A (zh) * 2016-12-14 2017-05-10 江南大学 一株酶活提高的苯丙氨酸脱氨酶突变体
CN106755160B (zh) * 2017-01-17 2019-08-02 湖州颐辉生物科技有限公司 一种组氨酸解氨酶及其用途
EP3579867A4 (en) * 2017-02-13 2021-03-10 Codexis, Inc. MANIPULATED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES
WO2018219108A1 (en) * 2017-05-27 2018-12-06 Enzymaster (Ningbo) Bio-Engineering Co., Ltd. Engineered aldolase polypeptides and uses thereof
US10900055B2 (en) 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
US11198861B2 (en) 2018-07-12 2021-12-14 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
CN113316635A (zh) * 2018-10-29 2021-08-27 科德克希思公司 工程化dna聚合酶变体
WO2020123286A1 (en) * 2018-12-14 2020-06-18 Codexis, Inc. Engineered tyrosine ammonia lyase
US20230183712A1 (en) * 2020-02-19 2023-06-15 Trustees Of Tufts College Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained
JP2023518184A (ja) * 2020-03-20 2023-04-28 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を軽減するように遺伝子改変された微生物
US20240316121A1 (en) * 2020-12-31 2024-09-26 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
CA3220735A1 (en) * 2021-05-21 2022-11-24 Codexis, Inc. Engineered methionine gamma lyase variants
CN114015636B (zh) * 2021-12-08 2023-09-29 天地壹号饮料股份有限公司 重组醋酸菌及其制备方法和应用
CN114457151B (zh) * 2022-01-27 2024-06-11 宁夏医科大学总医院 一种用于检测苯丙氨酸羟化酶基因突变的检测试剂盒及其检测方法
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN115518691B (zh) * 2022-10-14 2023-11-21 天津大学 一种具有类漆酶活性的人工酶及制备方法和应用
CN115873837A (zh) * 2022-11-18 2023-03-31 安徽盈科生物科技有限公司 高表达的新型的苯丙氨酸解氨酶
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株
WO2025063255A1 (ja) * 2023-09-19 2025-03-27 積水化学工業株式会社 アンモニアリアーゼおよびその用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US603344A (en) 1898-05-03 Trough for well-curbs
US753653A (en) 1903-09-14 1904-03-01 American Car & Foundry Co Hopper-bottom car.
DK75593D0 (es) * 1993-06-25 1993-06-25 Novo Nordisk As
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
DK0765394T3 (da) 1994-06-03 2001-12-10 Novozymes As Oprensede Myceliopthora-laccaser og nukleinsyrer der koder for disse
DE69534185T2 (de) 1994-06-30 2006-02-23 Novozymes Biotech, Inc., Davis Nicht-toxisches, nicht-toxigenes, nicht-pathogenes fusarium expressionssystem und darin zu verwendende promotoren und terminatoren
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP2261373A3 (en) 1997-01-17 2011-12-14 Codexis Mayflower Holdings, LLC Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
CA2313380C (en) 1997-12-08 2008-12-30 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
WO2000042561A2 (en) 1999-01-19 2000-07-20 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
AU3391900A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
EP1272967A2 (en) 2000-03-30 2003-01-08 Maxygen, Inc. In silico cross-over site selection
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
EP2315145B1 (en) 2002-03-01 2015-11-25 Codexis Mayflower Holdings, LLC Methods, systems, and software for identifying functional biomolecules
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
WO2003078583A2 (en) 2002-03-09 2003-09-25 Maxygen, Inc. Optimization of crossover points for directed evolution
US8003356B2 (en) 2004-04-20 2011-08-23 E. I. Du Pont De Nemours And Company Methods for the preparation of para-hydroxycinnamic acid and cinnamic acid at alkaline pH
JP2008513027A (ja) * 2004-09-17 2008-05-01 バイオマリン ファーマシューティカル インコーポレイテッド フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体
US20090038023A1 (en) 2005-03-10 2009-02-05 Verenium Corporation Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008069958A2 (en) * 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
CN102066561B (zh) 2008-06-13 2013-09-25 科德克希思公司 合成多核苷酸变体的方法
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
JP5828844B2 (ja) * 2010-02-04 2015-12-09 ビオマリン プハルマセウトイカル インコーポレイテッド 原核生物フェニルアラニンアンモニアリアーゼ変異体の組成物、及び、その組成物を用いる方法
AU2011324862A1 (en) 2010-11-05 2013-05-30 Basf Plant Science Company Gmbh Method for increasing yield and fine chemical production in plants
WO2012122333A1 (en) 2011-03-08 2012-09-13 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Microbial conversion of glucose to styrene and its derivatives
US20130005012A1 (en) 2011-06-23 2013-01-03 Phytogene, Inc. Enzymatic system for monomer synthesis
KR102218930B1 (ko) 2013-04-18 2021-02-23 코덱시스, 인코포레이티드 조작된 페닐알라닌 암모니아 리아제 폴리펩티드

Also Published As

Publication number Publication date
LT2986722T (lt) 2019-09-10
AU2014253900A1 (en) 2015-11-12
US20200231959A1 (en) 2020-07-23
PH12015502412A1 (en) 2016-02-22
SG11201508598YA (en) 2015-11-27
CY1121891T1 (el) 2020-10-14
US20200040325A1 (en) 2020-02-06
US20190055536A1 (en) 2019-02-21
AU2019272057A1 (en) 2019-12-19
MY193198A (en) 2022-09-26
US20190241882A1 (en) 2019-08-08
DK3521423T3 (da) 2021-09-06
US11130947B2 (en) 2021-09-28
EP2986722B1 (en) 2019-04-03
US10160963B2 (en) 2018-12-25
JP2020185016A (ja) 2020-11-19
EP2986722A2 (en) 2016-02-24
WO2014172541A2 (en) 2014-10-23
JP7129715B2 (ja) 2022-09-02
EP2986722A4 (en) 2017-02-22
ES2729048T3 (es) 2019-10-30
AU2014253900B2 (en) 2019-09-19
US11913045B2 (en) 2024-02-27
US10144924B2 (en) 2018-12-04
EP3971288A1 (en) 2022-03-23
PT2986722T (pt) 2019-06-21
US9611468B2 (en) 2017-04-04
US20200032235A1 (en) 2020-01-30
IL242067B (en) 2018-03-29
EP3521423A1 (en) 2019-08-07
PH12015502412B1 (en) 2016-02-22
US10870843B2 (en) 2020-12-22
EA201591995A1 (ru) 2016-04-29
DK2986722T3 (da) 2019-05-13
JP6637410B2 (ja) 2020-01-29
US20200199566A1 (en) 2020-06-25
US11401515B2 (en) 2022-08-02
US20190040377A1 (en) 2019-02-07
PL2986722T3 (pl) 2019-10-31
CA2909719A1 (en) 2014-10-23
US10640759B2 (en) 2020-05-05
JP2020185017A (ja) 2020-11-19
US20190055535A1 (en) 2019-02-21
HUE055899T2 (hu) 2022-01-28
US20180016568A1 (en) 2018-01-18
WO2014172541A3 (en) 2015-02-19
BR112015026160A2 (pt) 2017-10-10
JP2016516428A (ja) 2016-06-09
HRP20190928T1 (hr) 2019-07-26
US20170191050A1 (en) 2017-07-06
US10975367B2 (en) 2021-04-13
KR20150143816A (ko) 2015-12-23
CN109486803A (zh) 2019-03-19
CN105324483B (zh) 2018-11-30
AU2019272057B2 (en) 2021-05-27
US10487319B2 (en) 2019-11-26
US20140314843A1 (en) 2014-10-23
US20210222146A1 (en) 2021-07-22
US20180037880A1 (en) 2018-02-08
US20200032233A1 (en) 2020-01-30
CA2909719C (en) 2022-09-27
MX366196B (es) 2019-07-01
US11136571B2 (en) 2021-10-05
SI2986722T1 (sl) 2019-07-31
HUE043549T2 (hu) 2019-08-28
CN109486803B (zh) 2022-10-25
US20200032236A1 (en) 2020-01-30
RS58802B1 (sr) 2019-07-31
JP2022183356A (ja) 2022-12-08
US10294468B2 (en) 2019-05-21
EP3521423B1 (en) 2021-07-21
JP2018166524A (ja) 2018-11-01
US10717974B2 (en) 2020-07-21
US10494623B2 (en) 2019-12-03
US10358639B2 (en) 2019-07-23
KR102218930B1 (ko) 2021-02-23
ES2890955T3 (es) 2022-01-25
US20200399627A1 (en) 2020-12-24
NZ713396A (en) 2020-06-26
US20200032234A1 (en) 2020-01-30
PE20151775A1 (es) 2015-12-02
SMT201900315T1 (it) 2019-07-11
AU2014253900C1 (en) 2020-04-02
US10941391B2 (en) 2021-03-09
EA034034B1 (ru) 2019-12-20
CN105324483A (zh) 2016-02-10

Similar Documents

Publication Publication Date Title
PH12015502412A1 (en) Engineered phenylalanine ammonia lyase polypeptides
PH12018501839A1 (en) St2l antagonists and methods of use
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX342920B (es) Metodo para purificar polipeptidos o inmunoconjugados activos.
EP2926460A4 (en) SYSTEMS AND METHODS FOR ENCODING AND DECODING NON-SYSTEMATIC IRA CODES WITH IRREGULAR CONTROL
IL240030A0 (en) 2-aza-bicyclo[1.2.2]heptane-3-carboxylic acid (benzyl-cyano-methyl)-modified amides inhibitors of cathepsin c
UA115231C2 (uk) Сполуки імідазопіролідинонів
EA201790876A1 (ru) Способ контроля, предотвращения или лечения кровотечения
UA117218C2 (uk) Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
PH12019501705A1 (en) Engineered phenylalanine ammonia lyase polypeptides
PH12016500598A1 (en) Protoxin-ii variants and methods of use
PH12015501627B1 (en) Kv1.3 antagonists and methods of use
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
EA201991896A1 (ru) Сконструированные полипептиды фенилаланин-аммиаклиазы
UA113976C2 (xx) Композиція солі n-(8-(2-гідроксибензоїл)аміно)каприлової кислоти і пептиду glp-1
HK1223560A1 (zh) 人造血紅素結合組合物及其用途
EA202092566A1 (ru) Фактор ix полипептиды и способы их использования

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration